CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 192 enrolled
Drug / intervention
FLUAD Quadrivalent +1 morebiological
Likely dose
FLUAD Quadrivalent 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06054269
NCT06054269Phase 3Completed
CompareCT.gov

Randomized Controlled Trial, Double Blind, Phase III, to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among Health Care Personnel (EDUCATE)

Centers for Disease Control and Prevention·interventional·Posted Sep 26, 2023·Updated May 19, 2026

In Brief

A Phase 3 clinical trial evaluating FLUAD Quadrivalent and FluQuadri for Influenza. Completed, enrolled 192 participants across 2 sites.

Detailed Summary

This randomized, double-blinded trial will assess humoral immune responses to adjuvanted, egg-based quadrivalent influenza vaccines compared to standard dose, egg-based quadrivalent influenza vaccines among healthcare personnel (HCP). The trial will be conducted at two sites in Lima, Peru during 2022 and 2023.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesPeru
CollaboratorsPeruvian Clinical Research, Hospital Nacional Cayetano Heredia, Hospital Nacional Arzobispo Loayza, U.S. Naval Medical Research Unit No.6 (NAMRU-6)

Timeline

Phase 3CompletedFinished
2023202420252026
First PostedSep 26, 2023
Enrollment StartNov 4, 2022
Primary CompletionJul 25, 2023
Study CompletionMay 4, 2026
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 2.8 years ago

Interventions

FLUAD Quadrivalentbiological

0.5 mL intramuscular dose of FLUAD Quadrivalent

FluQuadribiological

0.5 mL intramuscular dose of FluQuadri